We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Multimode Microplate Reader Emphasizes Label-Free Detection Technology

By LabMedica International staff writers
Posted on 01 Feb 2011
Drug discovery researchers now have the opportunity to upgrade their instrumentation to incorporate a new microplate reader that performs both optical label-free and traditional labeled assays. More...


This latest generation "EnSpire Multimode Plate Reader” boasts hardware designed by PerkinElmer, Inc. (Waltham, MA, USA) that is coupled with Corning Life Sciences (Corning, NY, USA) label-free "Epic” technology.

The reader's compact benchtop design combines Corning‘s Epic optical label-free technology with a range of classical labeled technologies, including quad monochromator-based absorbance and fluorescence intensity, ultrasensitive luminescence and patented Alpha technology in multiwell plate formats. Typically, Alpha technology kits are bead-based assays, using microparticles coated with either DNA or protein in a format suitable for use with automated reagent handling systems. Each AlphaScreen or AlphaLISA assay contains two bead types: donor beads, and acceptor beads. Binding of molecules captured on the beads leads to an energy transfer from one bead to the other, ultimately producing a luminescent or fluorescent signal.

The instrument can accommodate a portfolio of EnSpire label-free microplates that includes 384-well cellular and biochemical microplates, and 96-well cellular microplates.

These high performance microplates with proprietary coatings for label-free detection enable a wide range of biochemical and cellular assays. Automated liquid handling ensures the accuracy and consistency of results throughout the assay development process, and integrated software allows users to initiate assay development and data analysis more easily and simply.

Dr. Richard M. Eglen, president, bio-discovery at PerkinElmer, Inc., said, "Label-free technology represents a potential game-changer in drug discovery innovation, by offering researchers a universal platform to observe cellular interactions and the effects of possible new drug compounds on cells. This is a major improvement over the use of traditional labeled assay methods alone, which rely on more indirect and time-consuming methods of observation.”

Related Links:
PerkinElmer, Inc.
Corning Life Sciences


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.